AstraZeneca has paid $100m upfront fee for a novel preclinical lipoprotein (a) (Lp(a)) disruptor asset from China’s CSPC Pharmaceutical Group, signalling its intent on building a broad, sector-leading cardiovascular and metabolic portfolio.
Recent years have seen the UK-based big pharma establish a dominant position in oncology, and it is now building up a range of complementary assets to do the
Key Takeaways
-
The novel lipid-lowering asset helps AstraZeneca fill out its cardiovascular, renal and metabolism portfolio
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?